Thyroid C-cell tumors
0 FAERS reports across 0 drugs
Last updated 2026-05-28 15:46 UTCA thyroid C-cell tumor is a growth in the thyroid gland that starts in the C-cells, which are cells that normally make a hormone called calcitonin.
Plain-language definition of the term.
FDA labels for GLP-1 drugs including Mounjaro, Ozempic, Rybelsus, Saxenda, Trulicity, Victoza, Wegovy, Xultophy, and Zepbound mention thyroid C-cell tumors in their boxed warnings, contraindications, and warnings and precautions sections.
AI summary of the sources below.
FAERS report counts reflect voluntary adverse-event reports and cannot establish causation or true frequency; higher counts often track prescription volume. openFDA FAERS ↗
Reports by drug
No FAERS reports for this side effect in the current sample.
Mentioned in FDA labels
- Mounjaro
- Mounjaro
- Mounjaro
- Mounjaro
- Ozempic
- Ozempic
- Ozempic
- Ozempic
- Rybelsus
- Rybelsus
- Rybelsus
- Rybelsus
- Saxenda
- Saxenda
- Saxenda
- Saxenda
- Trulicity
- Trulicity
- Trulicity
- Trulicity
- Victoza
- Victoza
- Victoza
- Victoza
- Wegovy
- Wegovy
- Wegovy
- Xultophy
- Xultophy
- Xultophy
- Xultophy
- Zepbound
- Zepbound
- Zepbound
- Zepbound
Research mentioning thyroid c-cell tumors (10)
- Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies.
- A review on the association between glucagon-like peptide-1 receptor agonists and thyroid cancer.
- Changes in Serum Calcitonin Concentrations, Incidence of Medullary Thyroid Carcinoma, and Impact of Routine Calcitonin Concentration Monitoring in the EXenatide Study of Cardiovascular Event Lowering (EXSCEL).
- Glucagon-like peptide-1 analogues and thyroid cancer: An analysis of cases reported in the European pharmacovigilance database.
- Exenatide use and incidence of pancreatic and thyroid cancer: A retrospective cohort study.
- GLP-1 receptor agonist liraglutide inhibits the proliferation and migration of thyroid cancer cells.
- Risk of Thyroid Cancer Associated with Use of Liraglutide and Other Antidiabetic Drugs in a US Commercially Insured Population.
- Exploring Connections Between Weight-Loss Medications and Thyroid Cancer: A Look at the FDA Adverse Event Reporting System Database.
- No calcitonin change in a person taking dulaglutide diagnosed with pre-existing medullary thyroid cancer.
- Assessment of thyroid cancer risk associated with glucagon-like peptide 1 receptor agonist use.